13.07
-0.6(-4.39%)
Currency In USD
| Previous Close | 13.67 |
| Open | 13.55 |
| Day High | 13.41 |
| Day Low | 12.84 |
| 52-Week High | 17.75 |
| 52-Week Low | 6.99 |
| Volume | 1.89M |
| Average Volume | 2.37M |
| Market Cap | 1.56B |
| PE | -12.57 |
| EPS | -1.04 |
| Moving Average 50 Days | 14.57 |
| Moving Average 200 Days | 12.36 |
| Change | -0.6 |
If you invested $1000 in Arcutis Biotherapeutics, Inc. (ARQT) since IPO date, it would be worth $599.54 as of May 30, 2025 at a share price of $13.07. Whereas If you bought $1000 worth of Arcutis Biotherapeutics, Inc. (ARQT) shares 3 years ago, it would be worth $625.96 as of May 30, 2025 at a share price of $13.07.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire Inc.
Yesterday at 8:00 PM GMT
WESTLAKE VILLAGE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis m
Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older
GlobeNewswire Inc.
May 22, 2025 6:12 PM GMT
Once-daily ZORYVE foam provides powerful clearance and rapid itch relief from head to toe with no limitation on duration of useMore than half of the nearly 9 million people in the United States with plaque psoriasis experience scalp involvementHealth
New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice
GlobeNewswire Inc.
May 15, 2025 1:29 PM GMT
Arcutis convened the Genital Psoriasis Wellness Consortium, a multidisciplinary group of clinicians who are experts in their fieldsPublication includes 14 consensus statements aimed at improving diagnosis, treatment, outcomes, and shared decision-mak